DexCom Inc. ($DXCM) Stock Forecast: Down 5.0% Today

What is DexCom Inc.?

DexCom, Inc. (DXCM) specializes in continuous glucose monitoring systems for individuals with diabetes, experiencing a bearish movement in today's market.

Why is DexCom Inc. going down?

DXCM stock is down 5.0% on Sep 25, 2025 13:46

• An ongoing investigation related to investor claims may have introduced uncertainty and pessimism into the stock, resulting in its bearish movement.
• Increased bearish options activity by well-funded investors might have exacerbated the downward trend of DXCM shares.
• Allegations surrounding the sale of faulty G7 devices by Dexcom, leading to adverse events and FDA citations for unauthorized changes affecting accuracy, likely influenced the negative market sentiment and the stock's bearish movement.

DXCM Price Chart

DXCM Technical Analysis

DXCM News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM - DexCom ( NASDAQ:DXCM )

NEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. ( "DexCom" or the "Company" ) DXCM. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

https://www.benzinga.com/pressreleases/25/09/g47843596/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dexcom-inc-dxcm

Spotlight on DexCom: Analyzing the Surge in Options Activity - DexCom ( NASDAQ:DXCM )

Deep-pocketed investors have adopted a bearish approach towards DexCom DXCM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

https://www.benzinga.com/insights/options/25/09/47773520/spotlight-on-dexcom-analyzing-the-surge-in-options-activity

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA - DexCom ( NASDAQ:DXCM )

At least 60 Dexcom G7 users report hospitalization, with multiple deaths alleged. FDA cited Dexcom for unauthorized material changes that impacted accuracy. Up Next: Wall Street trader's 35-0 strategy goes public this week. See it first → Hunterbrook Media released a short report on ...

https://www.benzinga.com/markets/large-cap/25/09/47742074/short-report-alleges-dexcom-sold-faulty-g7-device-cited-by-fda

Trending Today

ZCash ($ZEC) Crypto Forecast: Down 8.4% Today

Litecoin ($LTC) Crypto Forecast: Up 4.6% Today

Wormhole ($W) Crypto Forecast: Down 6.3% Today

Hedera Hashgraph ($HBAR) Crypto Forecast: Up 10.4% Today

Petco Health and Wellness Co. Inc. ($WOOF) Stock Forecast: Up 5.0% Today

BlackLine, Inc. ($BL) Stock Forecast: Up 11.1% Today

Edwards Lifesciences Corporation ($EW) Stock Forecast: Up 5.8% Today

Kornit Digital Ltd. ($KRNT) Stock Forecast: Up 5.0% Today

NextEra Energy Inc. ($NEE) Stock Forecast: Up 2.7% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 5.5% Today

DexCom Inc. Price History

24.03.2025 - DXCM Stock was up 5.1%

• The rise in DXCM stock value could be linked to the disclosure of an inquiry by Bragar Eagel & Squire, P.C., which may have provided assurance to shareholders and demonstrated transparency in the company's activities.
• Shareholders may interpret this inquiry as a proactive measure to ensure responsibility and safeguard the interests of long-term investors, thereby fostering trust in DXCM's corporate governance.
• This development likely instilled optimism in investors, leading to an increase in the stock price as they anticipate a resolution that could bolster the company's standing and growth potential in the healthcare market.

02.04.2025 - DXCM Stock was up 9.5%

• Despite missing earnings estimates for Q1, DexCom (DXCM) saw a significant bullish movement in its stock price.
• The market's positive reaction could be linked to promising key metrics suggesting future company performance.
• Investors seem hopeful about DexCom's growth potential despite recent stock price decline, possibly due to confidence in its products and market position.
• The upward stock movement may also be influenced by general optimism in the healthcare sector, leading investors to view companies like DexCom favorably.

02.04.2025 - DXCM Stock was up 14.9%

• Despite DexCom's Q1 earnings missing estimates and lower margins, the stock experienced a strong bullish movement.
• The market seems to be optimistic about DXCM's future performance in 2025, driven by global growth in CGM adoption, strong sensor sales, and expansion into new markets.
• Investors may be focusing more on the company's potential growth opportunities rather than its current financial results, leading to the bullish movement in the stock.
• The recent increase in DXCM's stock price could also be attributed to positive market sentiment and potential future developments in the healthcare sector.

31.06.2025 - DXCM Stock was down 8.0%

• Despite surpassing Q2 earnings and increasing 2025 sales outlook, DXCM's stock faced a decline as margin pressure impacted investor sentiment.
• The company's strong financial results were overshadowed by worries about margins, resulting in the bearish movement of the stock.
• Expectations for better performance beyond the reported figures might have led to disillusionment among investors, contributing to the drop in stock value.

31.06.2025 - DXCM Stock was down 6.6%

• The noticeable decline in DXCM stock today is possibly linked to profit-taking by investors following a recent uptrend.
• While DexCom (DXCM) surpassed earnings and revenue expectations in Q2, the market reaction may reflect heightened anticipated results, resulting in a sell-off.
• Investor apprehension regarding DexCom's growth sustainability, coupled with uncertainties surrounding U.S. coverage expansion and Stelo's impact, could be influencing market sentiment.
• A shift in overall market sentiment, influenced by various factors, may be leading some traders to approach DXCM stock more cautiously.

19.08.2025 - DXCM Stock was down 5.5%

• The decline in DXCM stock today could be linked to a recent claim suggesting that the company sold faulty G7 devices flagged by the FDA. Incidents of hospitalizations and alleged deaths associated with the G7 device may have raised concerns among investors about the product's quality and regulatory consequences.
• Ongoing investigations by legal firms looking into potential claims and breaches of fiduciary duties by DexCom's executives could have contributed to the negative sentiment towards the stock, prompting the bearish market performance.
• Investor response may be tied to uncertainties and legal inquiries surrounding DexCom, Inc., influencing the stock's trajectory as stakeholders weigh the potential risks and ramifications of the investigations on the company's future prospects.

11.03.2025 - DXCM Stock was down 6.3%

• Dexcom's new 15-Day Wearable Glucose Management System recently received FDA approval but the stock faced bearish movement.
• The market's negative reaction could be related to profit-taking after a surge in price following the FDA clearance.
• Concerns about competition in the diabetes management sector from companies like Insulet, which are introducing compatible products, may have prompted investors to sell DXCM shares.
• The broader market downturn, with the Dow Jones index dropping over 800 points, likely influenced DXCM stock's bearish movement as investors sought safer assets amid market volatility.

25.08.2025 - DXCM Stock was down 5.0%

• An ongoing investigation related to investor claims may have introduced uncertainty and pessimism into the stock, resulting in its bearish movement.
• Increased bearish options activity by well-funded investors might have exacerbated the downward trend of DXCM shares.
• Allegations surrounding the sale of faulty G7 devices by Dexcom, leading to adverse events and FDA citations for unauthorized changes affecting accuracy, likely influenced the negative market sentiment and the stock's bearish movement.

22.04.2025 - DXCM Stock was down 1.8%

• The overall market sentiment towards DXCM has been bullish, largely influenced by its strong product portfolio.
• Today, there was a bearish movement in DXCM stock, possibly due to profit-taking by investors following a period of sustained growth despite the optimistic outlook on the company's products.

25.07.2025 - DXCM Stock was down 3.0%

• DXCM's expansion efforts and focus on innovation with type 2 access, Stelo adoption, and new sensor launches have been positive for the company.
• However, margin pressures, increasing competition, and a leadership transition may have contributed to investor concerns, leading to the bearish movement in the stock price.
• The balancing act between growth opportunities and challenges in the market could be causing uncertainty among investors, resulting in the downward trend for DXCM today.

24.05.2025 - DXCM Stock was up 6.2%

• Today, DXCM saw a significant uptrend driven by a surge in patient numbers and enhanced market presence in the Type 2 Diabetes segment.
• Despite encountering margin constraints and regulatory scrutiny, DXCM's operational resilience and expansion initiatives have overshadowed these obstacles, resulting in a favorable market reaction.
• Investors are enthusiastic about DXCM's adept handling of regulatory challenges and its potential to leverage the expanding patient base, thus pushing the stock price upwards.

10.03.2025 - DXCM Stock was up 14.0%

• DexCom's stock saw a strong bullish movement today amidst a broader market downturn, likely driven by several positive factors:
• PriceSmart's better-than-expected earnings and overall positive sentiment in the market could have boosted investor confidence in DXCM.
• The commercial launch of Omnipod 5 in Canada, which is compatible with Dexcom's CGM sensors, likely contributed to the positive outlook for DexCom.
• Investor optimism surrounding DexCom's strong product portfolio and potential for future growth could have also supported the bullish momentum in the stock today.